Tema Heart & Health ETF HRTS
39.45 USD -0.07 (-0.17%)
At closeNov 10, 2026, 4:00 PM EST
39.40 -0.05 -0.14%
After hours · Nov 10, 4:00 PM ET
39.28 Day range 39.45
32.59 52-week range 39.84
- YTD
- +11.80%
- 1 year
- +19.23%
News
zacks.com 4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.
zacks.com Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
zacks.com Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
zacks.com Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
businesswire.com Tema ETFs Exceeds $5bn in AUM After Three Years NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years…
zacks.com Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
benzinga.com From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.
zacks.com GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
businesswire.com Tema ETFs Surpasses $2 Billion in AUM in Under Three Years NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced that the firm has surpassed $2 billion in assets under…
benzinga.com Why Is Eli Lilly Stock Gaining Today? Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.
benzinga.com 'Roche Restricts Consulting Work With Big Four Firms To Cut Costs' - Bloomberg https://www.bloomberg.com/news/articles/2026-03-24/roche-restricts-consulting-work-with-big-four-firms-to-cut-costs?utm_source=latest&utm_medium=share&utm_campaign=copy
benzinga.com Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder Ultragenyx Phase 3 gene therapy data shows reduced ammonia levels in rare disease patients, with further results expected in 2027.
defenseworld.net Tema Heart & Health ETF (NASDAQ:HRTS) Shares Down 1.5% – Time to Sell? Tema Heart and Health ETF (NASDAQ: HRTS - Get Free Report) shares traded down 1.5% on Tuesday. The stock traded as low as $35.00 and last traded at $35.21. 6,130 shares traded hands during trading, a…
businesswire.com Tema Appoints ETF Industry Leader Steve Munroe as President NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this…
etftrends.com New Year, New Strategy: Navigating Weight Loss ETFs With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This…
defenseworld.net Flow Traders U.S. LLC Has $522,000 Stock Holdings in Tema Heart & Health ETF $HRTS Flow Traders U.S. LLC decreased its position in Tema Heart and Health ETF (NASDAQ: HRTS) by 67.6% during the undefined quarter, according to the company in its most recent filing with the SEC. The…
etftrends.com New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance…
etftrends.com Disruptive Theme of the Week: 2024's Top Investment Themes & Trends 2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.
benzinga.com EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.
etftrends.com Disruptive Theme of the Week – Breakthroughs in Medicine Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical…
zacks.com Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
benzinga.com EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line.
zacks.com Tap the Weight-Loss Drug Market With These ETFs Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
etftrends.com Disruptive Theme of the Week: Playing Defense When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
invezz.com How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS) The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.
seekingalpha.com HRTS: Generating Alpha In Obesity Treatment The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth…- benzinga.com EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
benzinga.com EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
benzinga.com Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed…